In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
2008
Efficacy of Anti-CEA Monoclonal Antibodies in Cancer Treatment
publication
Evidence: moderate
Author Information
Author(s): Blumenthal R D, Hansen H J, Goldenberg D M
Primary Institution: Garden State Cancer Center, Center for Molecular Medicine and Immunology
Hypothesis
Can unconjugated humanised anti-CEA monoclonal antibodies effectively treat colorectal cancer?
Conclusion
The study suggests that humanised anti-CEA monoclonal antibodies can provide direct anti-tumour effects and enhance chemotherapy in treating CEA-expressing cancers.
Supporting Evidence
- Humanised anti-CEA monoclonal antibodies have shown promising results in targeting cancer cells.
- The MN-14 antibody has been studied for its ability to inhibit tumor growth and enhance chemotherapy effects.
- Studies indicate that these antibodies can induce immune responses against cancer cells.
Takeaway
This study shows that certain antibodies can help fight cancer by targeting a specific protein found in cancer cells, making treatments more effective.
Methodology
The study involved both in vitro and preclinical studies using humanised anti-CEA monoclonal antibodies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website